Introduction
Bartter's syndrome is a heterogeneous disorder characterized by deficient renal sodium and chloride reabsorption, and hypokalemic metabolic alkalosis with hyperreninemia, hyperaldosteronemia. Affected patients present with normal or low blood pressure, hyperreninemia, hypokalemia, and a tendency towards hypercalciuria and nephrocalcinosis in the neonatal variant (1, 2) . Further abnormalities in the metabolism of calcium, calciotropic hormones, and inorganic phosphate have been noted, sometimes, in these disorders, although data characterizing the classic calciotropic hormone levels during stable phases of the condition are sparse (3) . Mutations in five genes that are expressed in the ascending limb have been identified in Bartter's syndrome, and the products of these genes either transport salt (three genes, types I-III ) or regulate salt transport ( types IV and V) (1). Type 5 Bartter's syndrome has been recently defined as a Bartter's syndrome due to the most activating mutations of the calcium-sensing receptor (CaSR) and may manifest with variable severity (4). CaSR is a G-protein coupled receptor essential for regulating secretion of parathyroid hormone. In addition to the parathyroid, CaSR is expressed in several other tissues, including the kidney. In fact, activating mutations of CaSR cause autosomal dominant hypocalcaemia associated with relative hypercalciuria (5) . We report a case with type 5 Bartter's syndrome, who presented with seizure and hypocalcemia.
Case Report
A 27-month-old boy was admitted to our hospital because of seizure and weakness and spasm in his extremities. A pediatric nephrologist had been following his since he was 6 months of age, with the diagnosis of typical Bartter's syndrome with hypokalemic metabolic alkalosis. A history of maternal polyhydramnios with prematurity elicited and triangular facies presented on physical examination was noted.
There was no family history of seizure or consanguinity. Ten days before he admitted with febrile convulsion. At the time of admission, patient was treated with spironolactone (2 mg/kg/d), potassium chloride 6% (6 mEq/ kg/d). Physical examination on admission showed weight and height under the third percentile. Consciousness, cranial nerves, respiratory muscles, and pain sensation were intact. Analysis of arterial blood showed mild metabolic alkalosis (pH 7.53, PaCO 2 49 mm Hg, PaO 2 93 mm Hg, bicarbonate 37.3 mEq/L). Serum electrolytes revealed severe hypokalemia (2.1 mEq/L), and serum sodium was 137 mEq/L. Initial serum biochemistry revealed the following; Calcium was 6.8 mg/dL, phosphorus was 11.3 mg/dL, alkaline phosphatase was 73 U/L, magnesium levels was 3.1 mg/dL. Blood urea nitrogen and creatinine were normal. Complete blood count was normal. QTc was prolonged (0.52 seconds). Other laboratory data were a decreased level of parathyroid hormone (PTH) concentration (8.4 ρg/mL) and 1,25(OH) 2 D 3 (7.8 ng/mL). Brain magnetic resonance imaging (MRI) was normal, however, electroencephalogram (EEG) was mildly abnormal. Patient was treated with spironolactone, potassium chloride, gluconate calcium and calcitriol accordingly. Calcium level normalized after treatment and patient discharged with good condition.
Discussion
The association between severe hypocalcaemia and characteristics of Bartter's syndrome reported in this patient. In our case, the diagnosis of Bartter's syndrome was confirmed by a biochemical analysis suggestive of Bartter's syndrome. Hypocalcaemia with suppressed secretion of PTH and high fractional excretion of calcium suggested activating mutations of CaSR. The extracellular CaSR plays an essential role in extracellular Ca 2+ homeostasis by regulating the rate of PTH secretion and the rate of calcium reabsorption by the kidney. Renal CaSR activation is thought to inhibit cation reabsorption of paracellular divalent in the cortical ascending limb both directly and indirectly via a decrease in NaCl transport (6). Bartter's syndrome type 5 has been described in association with four different heterozygous activating CaSR mutations (K29E, L125P, C131W and A843E). Of these, L125P, C131W and A843E were associated with classical features of Bartter's syndrome, including hypokalemic alkalosis and hyperreninemic hyperaldosteronism, and presented either in childhood or early adulthood. All affected patients had symptomatic hypocalcemia together with urinary calcium excretion elevations. In contrast, K29E was associated with a more limited phenotype characterized by mild hypokalemia and the absence of alkalosis (7). Vezzoli et al, reported two monozygotic twin sisters with autosomal dominant hypocalcemia (ADH) due to a nonconservative activating CaSR mutation in the extracellular domain (K29E). They developed a Bartter's-like syndrome characterized by a mild phenotype (4). Our case had typical Bartter's syndrome and presented in infancy. Molecular genetics studies are indicated to identify the primary genetic defect. A genetic study could not be performed in our case. Patra et al reported a case of a 4-month-old infant with neonatal Bartter's syndrome, who presented only with status epilepticus. The patient had severe hyponatremia, which presented as seizures. However, the patient did not have any typical clinical manifestations like facial failure to thrive, dysmorphism or any polyuria history, vomiting or other suggestive features (8) . Seizure in our case was due to hypocalcemia. Chrispal et al, reviewed a patient with developed severe renal tubular dysfunction secondary to short-term amikacin therapy, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis and polyuria. This biochemical abnormalities constellation, mimic type V Bartter's syndrome, where there is activating mutation of the calcium sensing receptor in the distal tubule and thick ascending loop of Henle. In this case, amikacin was triggered this activation of the calcium sensing receptor. This phenomenon has been described with gentamicin though never with amikacin. Tubular dysfunction recovery, took 15 days following cessation of the offending drug, amikacin (9) .
Conclusion
There are several subtypes of Bartter's syndrome with distinct phenotypes. Type 5 Bartter's syndrome results from mutation leading to upregulation of the CaSR and therefore hypocalcemia and hypercalciuria in addition to the typical salt-losing phenotype.
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